Coverage
-
April 12, 2017
Kissei Pharmaceutical and Allergan reached an agreement to dismiss all claims against Sandoz in litigation alleging the Novartis division infringed a patent for their enlarged-prostate medication Rapaflo by seeking approval for generic forms of the treatment, according to a Tuesday court filing in Delaware federal court.
2 other articles on this case.
View all »